Clinical trial
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
NCT00003895 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003895 |
|---|---|
| Title | Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma |
| Official title | A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a >1mm Melanoma on Initial Biopsy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma |
| Intervention type | Biological, Other |
| Interventions | HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | Apr 1, 1999 |
| Primary completion | Sep 1, 2013 |
| Completion | Sep 1, 2013 |
| First posted | Jul 18, 2003 |
| Last update posted | Feb 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: